BACKGROUND: Antenatal corticosteroids are given primarily to induce fetal lung maturation but results from meta-analyses of randomized controlled trials have not shown mortality or pulmonary benefits for extremely preterm infants although these are the infants most at risk of mortality and pulmonary disease. OBJECTIVE: We sought to determine if exposure to antenatal corticosteroids is associated with a lower rate of death and pulmonary morbidities by 36 weeks' postmenstrual age. STUDY DESIGN: Prospectively collected data on 11,022 infants 22 0/7 to 28 6/7 weeks' gestational age with a birthweight of ≥401 g born from Jan. 1, 2006, through Dec. 31, 2014, were analyzed. The rate of death and the rate of physiologic bronchopulmonary dysplasia by 36 weeks' postmenstrual age were analyzed by level of exposure to antenatal corticosteroids using models adjusted for maternal variables, infant variables, center, and epoch. RESULTS: Infants exposed to any antenatal corticosteroids had a lower rate of death (2193/9670 [22.7%]) compared to infants without exposure (540/1302 [41.5%]) (adjusted relative risk, 0.71; 95% confidence interval, 0.65-0.76; P < .0001). Infants exposed to a partial course of antenatal corticosteroids also had a lower rate of death (654/2520 [26.0%]) compared to infants without exposure (540/1302 [41.5%]); (adjusted relative risk, 0.77; 95% confidence interval, 0.70-0.85; P < .0001). In an analysis by each week of gestation, infants exposed to a complete course of antenatal corticosteroids had lower mortality before discharge compared to infants without exposure at each week from 23-27 weeks' gestation and infants exposed to a partial course of antenatal corticosteroids had lower mortality at 23, 24, and 26 weeks' gestation. Rates of bronchopulmonary dysplasia in survivors did not differ by antenatal corticosteroid exposure. The rate of death due to respiratory distress syndrome, the rate of surfactant use, and the rate of mechanical ventilation were lower in infants exposed to any antenatal corticosteroids compared to infants without exposure. CONCLUSION: Among infants 22-28 weeks' gestational age, any or partial antenatal exposure to corticosteroids compared to no exposure is associated with a lower rate of death while the rate of bronchopulmonary dysplasia in survivors did not differ.
BACKGROUND:Antenatal corticosteroids are given primarily to induce fetal lung maturation but results from meta-analyses of randomized controlled trials have not shown mortality or pulmonary benefits for extremely preterm infants although these are the infants most at risk of mortality and pulmonary disease. OBJECTIVE: We sought to determine if exposure to antenatal corticosteroids is associated with a lower rate of death and pulmonary morbidities by 36 weeks' postmenstrual age. STUDY DESIGN: Prospectively collected data on 11,022 infants 22 0/7 to 28 6/7 weeks' gestational age with a birthweight of ≥401 g born from Jan. 1, 2006, through Dec. 31, 2014, were analyzed. The rate of death and the rate of physiologic bronchopulmonary dysplasia by 36 weeks' postmenstrual age were analyzed by level of exposure to antenatal corticosteroids using models adjusted for maternal variables, infant variables, center, and epoch. RESULTS:Infants exposed to any antenatal corticosteroids had a lower rate of death (2193/9670 [22.7%]) compared to infants without exposure (540/1302 [41.5%]) (adjusted relative risk, 0.71; 95% confidence interval, 0.65-0.76; P < .0001). Infants exposed to a partial course of antenatal corticosteroids also had a lower rate of death (654/2520 [26.0%]) compared to infants without exposure (540/1302 [41.5%]); (adjusted relative risk, 0.77; 95% confidence interval, 0.70-0.85; P < .0001). In an analysis by each week of gestation, infants exposed to a complete course of antenatal corticosteroids had lower mortality before discharge compared to infants without exposure at each week from 23-27 weeks' gestation and infants exposed to a partial course of antenatal corticosteroids had lower mortality at 23, 24, and 26 weeks' gestation. Rates of bronchopulmonary dysplasia in survivors did not differ by antenatal corticosteroid exposure. The rate of death due to respiratory distress syndrome, the rate of surfactant use, and the rate of mechanical ventilation were lower in infants exposed to any antenatal corticosteroids compared to infants without exposure. CONCLUSION: Among infants 22-28 weeks' gestational age, any or partial antenatal exposure to corticosteroids compared to no exposure is associated with a lower rate of death while the rate of bronchopulmonary dysplasia in survivors did not differ.
Authors: Waldemar A Carlo; Scott A McDonald; Avroy A Fanaroff; Betty R Vohr; Barbara J Stoll; Richard A Ehrenkranz; William W Andrews; Dennis Wallace; Abhik Das; Edward F Bell; Michele C Walsh; Abbot R Laptook; Seetha Shankaran; Brenda B Poindexter; Ellen C Hale; Nancy S Newman; Alexis S Davis; Kurt Schibler; Kathleen A Kennedy; Pablo J Sánchez; Krisa P Van Meurs; Ronald N Goldberg; Kristi L Watterberg; Roger G Faix; Ivan D Frantz; Rosemary D Higgins Journal: JAMA Date: 2011-12-07 Impact factor: 56.272
Authors: P Brian Smith; Namasivayam Ambalavanan; Lei Li; C Michael Cotten; Matthew Laughon; Michele C Walsh; Abhik Das; Edward F Bell; Waldemar A Carlo; Barbara J Stoll; Seetha Shankaran; Abbot R Laptook; Rosemary D Higgins; Ronald N Goldberg Journal: Pediatrics Date: 2012-05-28 Impact factor: 7.124
Authors: Matthew A Rysavy; Lei Li; Edward F Bell; Abhik Das; Susan R Hintz; Barbara J Stoll; Betty R Vohr; Waldemar A Carlo; Seetha Shankaran; Michele C Walsh; Jon E Tyson; C Michael Cotten; P Brian Smith; Jeffrey C Murray; Tarah T Colaizy; Jane E Brumbaugh; Rosemary D Higgins Journal: N Engl J Med Date: 2015-05-07 Impact factor: 91.245
Authors: S F Bottoms; R H Paul; J D Iams; B M Mercer; E A Thom; J M Roberts; S N Caritis; A H Moawad; J P Van Dorsten; J C Hauth; G R Thurnau; M Miodovnik; P M Meis; D McNellis Journal: Am J Obstet Gynecol Date: 1997-05 Impact factor: 8.661
Authors: Ravi M Patel; Sarah Kandefer; Michele C Walsh; Edward F Bell; Waldemar A Carlo; Abbot R Laptook; Pablo J Sánchez; Seetha Shankaran; Krisa P Van Meurs; M Bethany Ball; Ellen C Hale; Nancy S Newman; Abhik Das; Rosemary D Higgins; Barbara J Stoll Journal: N Engl J Med Date: 2015-01-22 Impact factor: 91.245
Authors: Bradley N Manktelow; Mithilesh K Lal; David J Field; Sunil K Sinha Journal: Arch Dis Child Fetal Neonatal Ed Date: 2009-11-29 Impact factor: 5.747
Authors: Barbara J Stoll; Nellie I Hansen; Edward F Bell; Michele C Walsh; Waldemar A Carlo; Seetha Shankaran; Abbot R Laptook; Pablo J Sánchez; Krisa P Van Meurs; Myra Wyckoff; Abhik Das; Ellen C Hale; M Bethany Ball; Nancy S Newman; Kurt Schibler; Brenda B Poindexter; Kathleen A Kennedy; C Michael Cotten; Kristi L Watterberg; Carl T D'Angio; Sara B DeMauro; William E Truog; Uday Devaskar; Rosemary D Higgins Journal: JAMA Date: 2015-09-08 Impact factor: 56.272
Authors: Wes Onland; Filip Cools; Andre Kroon; Karin Rademaker; Maruschka P Merkus; Peter H Dijk; Henrica L van Straaten; Arjan B Te Pas; Thilo Mohns; Els Bruneel; Arno F van Heijst; Boris W Kramer; Anne Debeer; Inge Zonnenberg; Yoann Marechal; Henry Blom; Katleen Plaskie; Martin Offringa; Anton H van Kaam Journal: JAMA Date: 2019-01-29 Impact factor: 56.272
Authors: Hongpeng Jia; Chhinder P Sodhi; Yukihiro Yamaguchi; Peng Lu; Mitchell R Ladd; Adam Werts; William B Fulton; Sanxia Wang; Thomas Prindle; David J Hackam Journal: Shock Date: 2019-08 Impact factor: 3.454
Authors: Samuel J Gentle; Waldemar A Carlo; Sylvia Tan; Marissa Gargano; Namasivayam Ambalavanan; Sanjay Chawla; Edward F Bell; Carla M Bann; Susan R Hintz; Roy J Heyne; Alan Tita; Rosemary D Higgins Journal: Obstet Gynecol Date: 2020-06 Impact factor: 7.623
Authors: Hassendrini N Peiris; Roberto Romero; Kanchan Vaswani; Sarah Reed; Nardhy Gomez-Lopez; Adi L Tarca; Dereje W Gudicha; Offer Erez; Eli Maymon; Murray D Mitchell Journal: J Matern Fetal Neonatal Med Date: 2019-12-29